Table 3. Summary of fold increase in CD8⁺ T cell recognition of EBV-antigens presented by shBNLF2a-LCLs compared to shControl-LCLs.

					Fold increase
Expression phase of target antigen	Target antigen	Epitope	HLA restriction	Number of experiments*	Range	Median
IE	BRLF1	YVL	A2	11	6.5–30.7	17
IE	BZLF1	DPY	B7	4	7–14	8.3
E	BMLF1	GLC	A2	10	7–24	11.5
E	BMRF1	TLD	A2	5	7.5–12	9
E	BNLF2b	RPG	B7	4	4.1–7	5.5
L	BALF4	FLD	A2	11	2–5	2.3
L	BNRF1	WQW	A2	4	2.3–3	2.5
L	BNRF1	YPR	B7	4	2–3.5	2.5

* more than one effector clone specific for each epitope was used where possible. In total, seven different donor LCLs were used.